Invesco Biotechnology & Genome ETFInvesco Biotechnology & Genome ETFInvesco Biotechnology & Genome ETF

Invesco Biotechnology & Genome ETF

No trades
See on Supercharts

Key stats


Assets under management (AUM)
‪226.64 M‬USD
Fund flows (1Y)
‪−29.40 M‬USD
Dividend yield (indicated)
0.07%
Discount/Premium to NAV
0.04%
Shares outstanding
‪3.52 M‬
Expense ratio
0.58%

About Invesco Biotechnology & Genome ETF


Brand
Invesco
Home page
Inception date
Jun 23, 2005
Structure
Open-Ended Fund
Index tracked
Dynamic Biotech & Genome Intellidex Index (AMEX)
Replication method
Physical
Management style
Passive
Dividend treatment
Distributes
Distribution tax treatment
Qualified dividends
Income tax type
Capital Gains
Max ST capital gains rate
39.60%
Max LT capital gains rate
20.00%
Primary advisor
Invesco Capital Management LLC
Distributor
Invesco Distributors, Inc.
PBE is not a pure-play biotech fund, it goes beyond the scope of pure biotech firms and includes companies that benefit significantly from advances in biotech and genetic engineering. This causes PBE to differ from other biotech ETFs, therefore, it is important to note the funds portfolio before investing. Moreover, far from a plain-vanilla approach, PBE's underlying index uses a multifactor system (price momentum, earnings momentum, quality: ROE, asset turnover, FCF margin), management action, and value) to select 30 US stocks and weights them in tiers. The tiered weighting scheme creates a small-cap tilt. Top-ranked larger stocks receive 40% of index weight while the top-ranked smaller stocks are given 60%. The approach produces a unique portfolio of biotech and peripheral-industry companies. The fund is rebalanced and reconstituted quarterly starting each February. Prior to August 28, 2023, the fund traded under the name Invesco Dynamic Biotechnology & Genome ETF.

Classification


Asset Class
Equity
Category
Sector
Focus
Health care
Niche
Biotechnology
Strategy
Multi-factor
Geography
U.S.
Weighting scheme
Tiered
Selection criteria
Multi-factor
What's in the fund
Exposure type
StocksBonds, Cash & Other
Health Technology
Stock breakdown by region
97%2%
Top 10 holdings
Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Broaden your horizons with more funds linked to PBE via country, focus, and more.

Frequently Asked Questions


An exchange-traded fund (ETF) is a collection of assets (stocks, bonds, commodities, etc.) that track an underlying index and can be bought on an exchange like individual stocks.
PBE trades at 65.13 USD today, its price has risen 1.25% in the past 24 hours. Track more dynamics on PBE price chart.
PBE net asset value is 64.36 today — it's risen 2.71% over the past month. NAV represents the total value of the fund's assets less liabilities and serves as a gauge of the fund's performance.
PBE assets under management is ‪226.64 M‬ USD. AUM is an important metric as it reflects the fund's size and can serve as a gauge of how successful the fund is in attracting investors, which, in its turn, can influence decision-making.
PBE price has risen by 8.35% over the last month, and its yearly performance shows a 1.54% increase. See more dynamics on PBE price chart.
NAV returns, another gauge of an ETF dynamics, have risen by 2.71% over the last month, showed a −2.27% decrease in three-month performance and has increased by 1.22% in a year.
PBE fund flows account for ‪−29.40 M‬ USD (1 year). Many traders use this metric to get insight into investors' sentiment and evaluate whether it's time to buy or sell the fund.
Since ETFs work like an individual stock, they can be bought and sold on exchanges (e.g. NASDAQ, NYSE, EURONEXT). As it happens with stocks, you need to select a brokerage to access trading. Explore our list of available brokers to find the one to help execute your strategies. Don't forget to do your research before getting to trading. Explore ETFs metrics in our ETF screener to find a reliable opportunity.
PBE invests in stocks. See more details in our Analysis section.
PBE expense ratio is 0.58%. It's an important metric for helping traders understand the fund's operating costs relative to assets and how expensive it would be to hold the fund.
No, PBE isn't leveraged, meaning it doesn't use borrowings or financial derivatives to magnify the performance of the underlying assets or index it follows.
In some ways, ETFs are safe investments, but in a broader sense, they're not safer than any other asset, so it's crucial to analyze a fund before investing. But if your research gives a vague answer, you can always refer to technical analysis.
Today, PBE technical analysis shows the buy rating and its 1-week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1-month rating PBE shows the buy signal. See more of PBE technicals for a more comprehensive analysis.
Yes, PBE pays dividends to its holders with the dividend yield of 0.07%.
PBE trades at a premium (0.05%).
Premium/discount to NAV expresses the difference between the ETF’s price and its NAV value. A positive percentage indicates a premium, meaning the ETF trades at a higher price than the calculated NAV. Conversely, a negative percentage indicates a discount, suggesting the ETF trades at a lower price than NAV.
PBE shares are issued by Invesco Ltd.
PBE follows the Dynamic Biotech & Genome Intellidex Index (AMEX). ETFs usually track some benchmark seeking to replicate its performance and guide asset selection and objectives.
The fund started trading on Jun 23, 2005.
The fund's management style is passive, meaning it's aiming to replicate the performance of the underlying index by holding assets in the same proportions as the index. The goal is to match the index's returns.